HomeMarket NewsMicro Cap StocksExploring the Future of Psychedelics: Cybin's Recent Milestones, Musk and Ramaswamy's Perspective,...

Exploring the Future of Psychedelics: Cybin’s Recent Milestones, Musk and Ramaswamy’s Perspective, and Britney’s Unveiled Memoir

Actionable Trade Ideas

always free

psyched

Cybin Inc. Acquires Small Pharma and Receives International Patents

Cybin Inc. (NYSE: CYBN) and Small Pharma Inc. (OTC: DMTTF) have successfully completed their acquisition agreement, making Small Pharma a wholly-owned subsidiary of Cybin. This merger strengthens Cybin’s position in the psychedelics industry. Additionally, the company has recently been granted two patents by the United States Patent and Trademark Office (USPTO) and one patent by the European Patent Office (EP), further solidifying its intellectual property portfolio.

Elon Musk and Vivek Ramaswamy on the World Stage

Vivek Ramaswamy, a prominent Republican presidential candidate, and Elon Musk, CEO of Tesla (NASDAQ: TSLA), share a common interest in exploring the potential benefits of psychedelic drugs. Ramaswamy, known for his support of cannabis policy reform, believes psychedelics should be considered for therapeutic use. Both individuals have influenced the public discourse on mental health and the future of psychedelic medicine.

Decoding Britney Spears’ Revealing Memoir

In her memoir, β€œThe Woman in Me,” Britney Spears bares her soul, offering readers a glimpse into her life beyond the public persona. While her struggles under the media’s relentless scrutiny are well-known, Spears’ story also shines a light on her personal battles with drugs, depression, and the complexities of her relationship with Justin Timberlake. The memoir uncovers raw emotions and vulnerable moments, humanizing a global superstar.

The Wonderland Awards: Honoring Psychedelic Pioneers

The upcoming Third Annual Wonderland Awards, held in Miami, celebrates the individuals and organizations at the forefront of psychedelic research, mental health innovation, and transformative practices. Among the notable nominees is Javier Hasse, a leading voice in cannabis, hemp, CBD, and psychedelics journalism. Hasse’s extensive journalistic contributions and diverse talents have made him a prominent figure in the industry.

Psychedelics ETF Performance Update

The AdvisorShares Psychedelics ETF (NYSE: PSIL) experienced mixed performance during the week. The ETF opened at $1.41 on Monday, slightly lower than previous weeks, and closed at the same price on Friday. Throughout the week, the ETF reached a high of $1.44 on Monday and a low of $1.35 on Wednesday and Thursday.

Top Performers in the Psychedelics Stock Market

  • GH Research (NASDAQ: GHRS) closed at $6.91.
  • COMPASS Pathways (NASDAQ: CMPS) closed at $5.28.
  • Mind Medicine (MindMed) (NASDAQ: MNMD) closed at $2.47.
  • Enveric Biosciences (NASDAQ: ENVB) closed at $1.8.
  • Bright Minds Biosciences (NASDAQ: DRUG) closed at $1.4.
  • Silo Pharma (NASDAQ: SILO) closed at $1.34.
  • Atai Life Sciences (NASDAQ: ATAI) closed at $1.06.
  • Incannex Healthcare (NASDAQ: IXHL) closed at $0.99.
  • FSD Pharma (NASDAQ: HUGE) closed at $0.98.
  • Cybin Inc. (NYSE: CYBN) closed at $0.62.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.